



Financial Tear Sheet

CORPORATE PROFILE

Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony™ Platform to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.

PRIMARY IR CONTACT


LifeSci Advisors, LLC
 Jeremy Feffer
 Phone: (212) 915-2568
 E-mail: jeremy@lifesciadvisors.com

STOCK PERFORMANCE

ONS (Share)

Exchange	NASDAQ (US Dollar)
Price	\$0.90
Change (%)	▲ 0.05 (5.88%)
Volume	161,125
Today's Open	\$0.85
Previous Close	\$0.85
Intraday High	\$0.92
Intraday Low	\$0.83
52 Week High	\$2.30
52 Week Low	\$0.78

Data as of 06/15/18 4:00 p.m. ET



LATEST NEWS

June 13, 2018

Oncobiologics Enters Into First CDMO Contract

June 08, 2018

Oncobiologics Closes Second Tranche Of \$15 Million Private Placement

June 04, 2018

Stelis Biopharma And Oncobiologics To Unveil Bio2Source CDMO Offering At BIO 2018

UPCOMING EVENTS

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
05/16/18	25-NSE
05/15/18	10-Q
05/15/18	8-K
05/02/18	8-K

Data provided by Nasdaq. Minimum 15 minutes delayed.